Researchers described a GMP-compliant, semi-automated manufacturing platform to generate clinical-grade extracellular vesicles (EVs) from Wharton’s jelly-derived mesenchymal stromal cells. The system produced consistent product quality and demonstrated one-year frozen stability, addressing a core translational barrier for EV therapeutics: reproducible manufacturing. By validating a platform approach rather than a one-off protocol, the work targets scale-out readiness for CGT-adjacent therapies that still struggle with lot-to-lot variability. For EV developers, the signal is that regulatory-grade workflows are becoming more concrete—supporting future trial manufacturing packages and comparability studies.